MedTrace Logo

Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine

NCT05238649 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2022-03-29

No results posted yet for this study

Summary

A Randomized, Double Blind, Positive Control Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines

Conditions

  • COVID-19 Pandemic

Interventions

BIOLOGICAL

Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg

The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.

BIOLOGICAL

Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg

The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.

BIOLOGICAL

SARS-Cov-2 Vaccine Inactivated

The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.

Sponsors & Collaborators

  • Livzon Pharmaceutical Group Inc.

    lead INDUSTRY

Principal Investigators

  • Ligong Lu, Dr. · Zhuhai People's Hospital Medical Group

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-10
Primary Completion
2022-11-30
Completion
2023-01-28

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05238649 on ClinicalTrials.gov